company background image
CMPX logo

Compass Therapeutics NasdaqCM:CMPX Stock Report

Last Price

US$2.65

Market Cap

US$364.6m

7D

1.9%

1Y

90.6%

Updated

26 Jan, 2025

Data

Company Financials +

Compass Therapeutics, Inc.

NasdaqCM:CMPX Stock Report

Market Cap: US$364.6m

CMPX Stock Overview

A clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More details

CMPX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Compass Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Compass Therapeutics
Historical stock prices
Current Share PriceUS$2.65
52 Week HighUS$3.13
52 Week LowUS$0.77
Beta0.75
1 Month Change81.51%
3 Month Change57.74%
1 Year Change90.65%
3 Year Change41.71%
5 Year Changen/a
Change since IPO-68.82%

Recent News & Updates

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Sep 28
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20
Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

Shareholder Returns

CMPXUS BiotechsUS Market
7D1.9%3.6%1.8%
1Y90.6%-3.7%24.9%

Return vs Industry: CMPX exceeded the US Biotechs industry which returned -3.7% over the past year.

Return vs Market: CMPX exceeded the US Market which returned 25% over the past year.

Price Volatility

Is CMPX's price volatile compared to industry and market?
CMPX volatility
CMPX Average Weekly Movement17.1%
Biotechs Industry Average Movement11.3%
Market Average Movement6.5%
10% most volatile stocks in US Market18.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CMPX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CMPX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201432Tom Schuetzwww.compasstherapeutics.com

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.

Compass Therapeutics, Inc. Fundamentals Summary

How do Compass Therapeutics's earnings and revenue compare to its market cap?
CMPX fundamental statistics
Market capUS$364.61m
Earnings (TTM)-US$47.76m
Revenue (TTM)US$850.00k

429.0x

P/S Ratio

-7.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMPX income statement (TTM)
RevenueUS$850.00k
Cost of RevenueUS$0
Gross ProfitUS$850.00k
Other ExpensesUS$48.61m
Earnings-US$47.76m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin100.00%
Net Profit Margin-5,618.47%
Debt/Equity Ratio0%

How did CMPX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/26 10:30
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Compass Therapeutics, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.